FDA Pre-market Approval for Remodulin Delivery with Implantable System Pending
United Therapeutics Corporation recently announced that Medtronic, Inc., the world’s third largest medical device company, has forwarded a pre-market approval application to the U.S. Food and Drug Administration (FDA) for their proprietary SynchroMed® II implantable drug infusion system, along with a new catheter, to be used with United Therapeutics’s Remodulin® (treprostinil) injectable, formulated for intravenous treatment of…